APO866 lacks efficacy in cutaneous T-cell lymphoma
medwireNews: The nicotinamide adenine dinucleotide biosynthesis inhibitor APO866 does not show efficacy in patients with cutaneous T-cell lymphoma, according to phase II trial results reported in JAMA Dermatology.
Of 12 patients with relapsed or refractory disease who received up to three cycles of intravenous APO866 at a dose of 0.126 mg/m2 per hour, just one patient achieved a partial response at 16 weeks. Six patients had stable disease while the remaining five patients progressed.
The majority (86%) of patients experienced mild or moderate side effects, and the toxicity profile of the drug was deemed “reasonable” by Reinhard Dummer (University Hospital of Zurich, Switzerland) and team.
But given the lack of efficacy, the trial was terminated early and the authors “do not see a justification for further development of APO866 in [cutaneous T-cell lymphoma]”.
They do believe, however, that “owing to its mode of action with immunosuppression and insulin-mimicking effects, APO866 might play a role the treatment of other conditions.”
medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2016